Hybridoma Sequencing
What Is Hybridoma Sequencing?
Hybridoma sequencing is a specialized approach for determining the complete nucleotide sequences of antibody genes expressed by hybridoma cell lines. These hybridoma cells—created by fusing antibody-producing B cells with immortalized myeloma cells—are a primary source for monoclonal antibody (mAb) production. Sequencing the immunoglobulin heavy (IGH) and light (IGK/IGL) chain variable regions provides essential insights into the identity, specificity, and functional properties of these antibodies.
At AUGenomics, our hybridoma sequencing service employs next-generation sequencing (NGS) to accurately capture the V(D)J rearrangements and complementarity-determining regions (CDRs) that define antigen-binding specificity. This approach overcomes limitations of traditional Sanger sequencing by enabling deeper coverage, detection of low-frequency variants, and full-length gene assembly.
By identifying the exact antibody sequences, hybridoma sequencing enables researchers to protect intellectual property, reproduce antibody production, and engineer improved therapeutic candidates.
Advantages of Hybridoma Sequencing
01
Full Antibody Gene Coverage: Captures complete variable regions of both heavy and light chains.
02
High-Throughput NGS: Provides deeper coverage and higher accuracy than conventional sequencing methods.
03
Variant Detection: Identifies rare sequence variants or mutations that may affect binding or function.
04
Species Flexibility: Supports hybridomas derived from human, mouse, rat, and other species.
05
Low Input Requirements: High-quality results from minimal amounts of RNA or DNA.
06
Customizable Workflows: Tailored enrichment strategies for difficult or low-yield hybridomas.
07
Advanced Bioinformatics: Delivers assembled sequences, CDR annotations, and ready-to-use data for cloning or engineering.
08
IP Protection: Provides validated antibody sequences for patent filing and regulatory documentation.
09
Expert Guidance: Consultation from project design through downstream applications.
10
Fast Turnaround: Standard results delivered in 2–3 weeks, with expedited options for urgent projects.
Hybridoma sequencing is critical for applications where antibody identity and reproducibility are essential. Common uses include:
-
Monoclonal Antibody Characterization: Confirming the sequences of therapeutic or research-grade mAbs.
-
Antibody Engineering: Providing template sequences for humanization, affinity maturation, or other modifications.
-
Patent and IP Support: Generating validated sequence data for intellectual property protection and regulatory filings.
-
Lot-to-Lot Consistency: Ensuring genetic stability and sequence fidelity in hybridoma lines over time.
-
Antibody Recovery from Frozen Lines: Retrieving sequence information from archived hybridomas to restore antibody production.
-
Cross-Species Antibody Discovery: Profiling antibodies derived from mouse, rat, rabbit, or other hybridoma systems.
-
Therapeutic Development: Supporting preclinical antibody candidates with validated genetic data.
What is Hybridoma Sequencing Used For?
Hybridoma Sequencing with AUGenomics
Sample Submission
-
Accepted sample types: Hybridoma cell pellets or purified RNA
-
Recommended input: ≥1 million cells or ≥100 ng high-quality RNA
-
Preservation: RNA stabilizer preferred if shipping cell pellets
-
Output: Full-length variable region sequences (V_H and V_L), optionally with constant region typing
Please refer to our Shipping Guidelines for project-specific guidance.
Turnaround Time
Standard turnaround is 2–3 weeks, depending on sample quality and RNA extraction requirements. Expedited options are available depending on project scope and sequencing depth.
Frequently Asked Questions (FAQs)
Q: Can you sequence both heavy and light chains?
A: Yes. We sequence full V_H and V_L regions and can also report isotype information if desired.
Q: What if I only have frozen hybridoma cells?
A: That’s fine—we can extract RNA from frozen pellets. Please include enough cells and avoid repeated freeze-thaw cycles.
Q: Is sequence validation included?
A: Yes. We perform quality control checks, sequence assembly, and optional BLAST alignment to ensure accuracy.
Q: What types of hybridomas do you accept?
A: We support hybridomas derived from human, mouse, rat, rabbit, and other species commonly used in monoclonal antibody production.
Q: What sample material is required?
A: Typically, RNA extracted from hybridoma cells is preferred for accurate sequencing, but genomic DNA can also be used in certain workflows.
Q: How does NGS compare to traditional sequencing for hybridomas?
A: Unlike Sanger sequencing, NGS provides full coverage, detects low-frequency variants, and minimizes the risk of missing mutations.
Q: What is the typical sequencing depth and turnaround time?
A: Standard projects are completed in 2–3 weeks, with read depths optimized to capture full-length antibody variable regions.
Got more questions? Contact our team and get a free consultation anytime. info@augenomics.com
Glossary of Terms
-
Hybridoma: A cell line formed by fusing a B cell with a myeloma cell, used for producing monoclonal antibodies.
-
V_H/V_L regions: Variable regions of antibody heavy and light chains responsible for antigen recognition.
-
Monoclonal antibody (mAb): Antibody derived from a single B-cell clone, highly specific to a single epitope.
-
Isotype: The class of antibody (e.g., IgG, IgM) determined by the constant region of the heavy chain.
-
Recombinant expression: Producing antibodies in vitro using cloned variable region sequences.
